Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (CPRX)
NASDAQ:CPRX
CPRX Stock Chart & Stats
$25.06
-$0.35(-1.79%)
At close: 4:00 PM EST
$25.06
-$0.35(-1.79%)
Day’s Range― - ―
52-Week Range$19.05 - $26.58
Previous CloseN/A
Volume328.11K
Average Volume (3M)1.04M
Market Cap
$3.08B
Enterprise Value$2.25B
Total Cash (Recent Filing)$689.89M
Total Debt (Recent Filing)$2.89M
Price to Earnings (P/E)14.0
Beta0.68
Next Earnings
Mar 18, 2026EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.42
Shares Outstanding122,912,384
10 Day Avg. Volume1,112,260
30 Day Avg. Volume1,036,459
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)3.40
Price to Sales (P/S)5.03
P/FCF Ratio10.33
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue3.89
Enterprise Value/Gross Profit4.66
Enterprise Value/Ebitda7.40
Forecast
1Y Price Target
$34.33Price Target Upside36.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial LaunchHigh payer approval rates combined with a streamlined fulfillment process accelerate patient access to Agamree and support sustained revenue expansion.
Legal And Competitor Manufacturing SetbacksFDA inspection issues at a competitor's manufacturing facility plus stalled settlement talks increase the probability that the brand retains effective market exclusivity, protecting Firdapse market share.
Oncology Market ExpansionGuideline updates and wider adoption of targeted testing in oncology centers expand identification of cancer-associated LEMS patients, creating a sizeable growth runway for Firdapse.
Bears Say
Capital ConstraintsLimited willingness to use debt for financing restricts ability to fund higher-risk clinical-stage programs, potentially slowing pipeline advancement.
Generic CompetitionEntry of multiple generics is expected to materially erode Fycompa revenue, posing downside pressure on future performance.
Patent Litigation RiskInherent unpredictability of patent litigation outcomes creates material uncertainty around future market access for key products.
Catalyst Pharma News
CPRX FAQ
What was Catalyst Pharma’s price range in the past 12 months?
Catalyst Pharma lowest stock price was $19.05 and its highest was $26.58 in the past 12 months.
What is Catalyst Pharma’s market cap?
Catalyst Pharma’s market cap is $3.08B.
When is Catalyst Pharma’s upcoming earnings report date?
Catalyst Pharma’s upcoming earnings report date is Mar 18, 2026 which is in 40 days.
How were Catalyst Pharma’s earnings last quarter?
Catalyst Pharma released its earnings results on Nov 05, 2025. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.332 by $0.088.
Is Catalyst Pharma overvalued?
According to Wall Street analysts Catalyst Pharma’s price is currently Undervalued.
Does Catalyst Pharma pay dividends?
Catalyst Pharma does not currently pay dividends.
What is Catalyst Pharma’s EPS estimate?
Catalyst Pharma’s EPS estimate is 0.34.
How many shares outstanding does Catalyst Pharma have?
Catalyst Pharma has 122,912,384 shares outstanding.
What happened to Catalyst Pharma’s price movement after its last earnings report?
Catalyst Pharma reported an EPS of $0.42 in its last earnings report, beating expectations of $0.332. Following the earnings report the stock price went down -1.824%.
Which hedge fund is a major shareholder of Catalyst Pharma?
Currently, no hedge funds are holding shares in CPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Catalyst Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.33 (36.99% Upside)
$34.33 (36.99% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $878.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.2%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.53%
12-Months-Change
Fundamentals
Return on Equity
27.52%
Trailing 12-Months
Asset Growth
36.22%
Trailing 12-Months
Company Description
Catalyst Pharma
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
CPRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Catalyst Pharmaceuticals' strong financial performance, driven by significant growth in FIRDAPSE and AGAMREE, as well as the company's solid cash position and raised revenue guidance. However, the decline in FYCOMPA revenue due to generic competition and ongoing patent litigation for FIRDAPSE were noted challenges.View all CPRX earnings summariesCPRX Stock 12 Month Forecast
Average Price Target
$34.33
▲(36.99% Upside)
Technical Analysis
Amicus
―
Travere Therapeutics
―
Ocular Therapeutix
―
ImmunityBio
―
Liquidia Technologies
―
Ownership Overview
6.14% Insiders
17.58% Mutual Funds
0.36% Other Institutional Investors
49.20% Public Companies and Individual Investors